Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Comprender los cambios en el informe GOLD EPOC de 2024 a 2025

Comprender los cambios en el informe GOLD EPOC de 2024 a 2025

Las directrices de la Global Strategy for the diagnosis, management and prevention of Chronic Pulmonary Disease (GOLD) proporcionan estrategias basadas en la evidencia para el diagnóstico y el tratamiento de la Enfermedad Pulmomar Obstructiva Crónica (EPOC). La actualización GOLD 2025 ha perfeccionado las secciones sobre diagnóstico y manejo de la EPOC y refleja las últimas evidencias sobre las nuevas terapias recomendadas. 

Využití profylaxe žilní tromboembolie (VTE) po resekci kolorektálního karcinomu v souladu s doporučenými postupy zůstává i nadále nízké

Využití profylaxe žilní tromboembolie (VTE) po resekci kolorektálního karcinomu v souladu s doporučenými postupy zůstává i nadále nízké

Betazellfunktion bei T1D: entscheidend für Verlauf

Betazellfunktion bei T1D: entscheidend für Verlauf

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results